Why the study?
Inflammation-associated thrombosis is a major source of mortality and morbidity worldwide, prompting the need to manipulate inflammation-associated coagulation safely.
Do PVAX and Hep-DOCA nanodrugs (HDP) reduce inflammation and coagulation safely in models of inflammation-associated thrombosis?
Do PVAX and Hep-DOCA nanodrugs (HDP) reduce inflammation and coagulation safely in models of inflammation-associated thrombosis?
Co-assembled PVAX and Hep-DOCA nanoparticles represent a promising and safe nanomedicine approach for treating inflammation-associated thrombosis.
Answers are grounded in this paper and cite their sources.
May reduce inflammation-associated thrombosis via targeted nanoparticle delivery; preclinical data leave clinical translation open.
Inflammation-associated thrombosis is a non-negligible source of mortalities and morbidities worldwide. To manipulate inflammation-associated coagulation, nanoparticles that contain anti-inflammatory polymer (copolyoxalate containing vanillyl alcohol, PVAX) and anti-thrombotic heparin derivative deoxycholic acid (Hep-DOCA) are prepared. The strategy takes advantage of the reducted side effects of heparin through heparin conjugation, achievement of long-term anti-inflammation by inflammation-trigged release of anti-inflammatory agents, and formation of PVAX/heparin-DOCA nanoparticles by co-self-assembly. It is demonstrated that the Hep-DOCA conjugate and PVAX are synthesized successfully; PVAX and Hep-DOCA nanodrugs (HDP) are obtained by co-assembly; the HDP nanoparticles effectively reduce the inflammation and coagulation without inducing lethal bleeding both in vivo and in vitro. The method provided here is versatile and effective, which paves new way to develop nanodrugs to treat inflammation-associated thrombosis safely.
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: